Melbourne-based Prana Biotechnology welcomed the release of data which indicates its drug candidate PBT434 shows significant disease-modifying capability in multiple animal models of Parkinson's Disease, or PD, with potential utility in a range of movement disorders. PBT434 prevents alpha synuclein from aggregating and also prevents the toxic consequences of iron combining with dopamine. In a further sign of the potential of PBT434 as an effective treatment, its therapeutic benefits were seen to be dose-dependent. Increasing increments of the drug resulted in increased preservation of neurons and increased improvement in motor function.
- Health Care Industry
- drug candidate